Cometriq

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff
GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff
Endpoints
GSK
Cabometyx
Cometriq
Royalty Pharma
Flag link:
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Motley Fool
Exelixis
FDA
Cabometyx
Cometriq
advanced renal cell carcinoma
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:
3 Things Exelixis Must Do to Survive and Thrive in 2017
3 Things Exelixis Must Do to Survive and Thrive in 2017
Motley Fool
Exelixis
cabozantinib
Cabometyx
Cometriq
Flag link:
Kidney Cancer Drug Boxing Match
Kidney Cancer Drug Boxing Match
Motley Fool
kidney cancer
Bristol-Myers Squibb
Novartis
Exelixis
Opdivo
Cometriq
Afinitor
Flag link:
Cometriq Plays Wallflower As Opdivo's Dance Card Fills
Cometriq Plays Wallflower As Opdivo's Dance Card Fills
Seeking Alpha
Bristol-Myers Squibb
Opdivo
Cometriq
Exelixis
kidney cancer
Flag link:
Novartis bullish on Afinitor cancer drug despite new competition
Novartis bullish on Afinitor cancer drug despite new competition
Yahoo/Reuters
Novartis
Afinitor
Opdivo
Cometriq
Exelixis
Bristol-Myers Squibb
Flag link:
Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech
Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech
Forbes
Exelixis
kidney cancer
Cometriq
Flag link:
Exelixis to Investors: "Wait for It... No, Seriously, Wait for It!"
Exelixis to Investors: "Wait for It... No, Seriously, Wait for It!"
Motley Fool
Exelixis
Cobimetinib
vemurafenib
Cometriq
Flag link:
Is This the Year Exelixis Excels?
Is This the Year Exelixis Excels?
Morningstar
Exelixis
Cometriq
prostate cancer
Flag link:
An Excellent Investment in the Biotech Space?
An Excellent Investment in the Biotech Space?
Motley Fool
Cometriq
medullary thyroid cancer
Exelixis
Flag link:
Will the Exelixis Hype Catch Up to Its Valuation?
Will the Exelixis Hype Catch Up to Its Valuation?
Motley Fool
Exelixis
Cometriq
medullary thyroid cancer
Flag link:
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Yahoo/BusinessWire
Exelixis
Cometriq
thyroid cancer
medullary thyroid cancer
Flag link:
Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players
Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players
Motley Fool
thyroid cancer
Caprelsa
AstraZeneca
Cometriq
Exelixis
Nexavar
Bayer
ONYX Pharmaceuticals
Flag link:
Where Is Exelixis In The Cancer Therapeutics Market?
Where Is Exelixis In The Cancer Therapeutics Market?
Seeking Alpha
Exelixis
cabozantinib
Cometriq
cancer
Flag link:
JPMorgan Healthcare Conference Highlights: Exelixis
JPMorgan Healthcare Conference Highlights: Exelixis
Motley Fool
Exelixis
JPMHC 2013
Cometriq
medullary thyroid cancer
Flag link:
Exelixis' Crowning Achievement
Exelixis' Crowning Achievement
Motley Fool
Exelixis
cabozantinib
Cometriq
thyroid cancer
medullary thyroid cancer
Flag link:
Exelixis Wins First Approval of Cancer Drug
Exelixis Wins First Approval of Cancer Drug
Minyanville
medullary thyroid cancer
Exelixis
Cometriq
Flag link: